Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma

This study is ongoing, but not recruiting participants.

Study NCT00436800. Last updated on July 7, 2008. Information provided by Sanofi-Aventis

Please refer to this study by its ClinicalTrials.gov identifier: NCT00436800

Locations


Hong Kong
	Sanofi-Aventis
	Hong Kong, Hong Kong

Sponsors and Collaborators

Sanofi-Aventis

Investigators


Study Director:	Iris Chan	Sanofi-Aventis